ES2159400T3 - Comprimido con liberacion controlada de clorhidrato de alfuzosina - Google Patents
Comprimido con liberacion controlada de clorhidrato de alfuzosinaInfo
- Publication number
- ES2159400T3 ES2159400T3 ES97937651T ES97937651T ES2159400T3 ES 2159400 T3 ES2159400 T3 ES 2159400T3 ES 97937651 T ES97937651 T ES 97937651T ES 97937651 T ES97937651 T ES 97937651T ES 2159400 T3 ES2159400 T3 ES 2159400T3
- Authority
- ES
- Spain
- Prior art keywords
- layer
- polymers
- chlorhydrate
- hydrophyl
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
COMPRIMIDO FARMACEUTICO DESTINADO A ADMINISTRACION POR VIA ORAL, PARA LA LIBERACION CONTROLADA DE CLORHIDRATO DE ALFUZOSINA EN SEGMENTOS PROXIMALES DEL TRACTO GASTROINTESTINAL, COMPRIMIDO CARACTERIZADO PORQUE ESTA CONSTITUIDO POR A) UNA PRIMERA CAPA (1) QUE TIENE LA PROPIEDAD DE INFLARSE NOTABLE Y RAPIDAMENTE EN CONTACTO CON LOS LIQUIDOS BIOLOGICOS ACUOSOS, PRODUCIENDOSE DICHA CAPA POR COMPRESION DE UNA MEZCLA O DE UN GRANULADO QUE COMPRENDE POLIMEROS HIDROFILOS QUE CONSTITUYEN ENTRE UN 0,50 Y UN 90 % Y PREFERENTEMENTE ENTRE UN 10 Y UN 85 % DE PESO DE LA CAPA, B) UNA SEGUNDA CAPA (2) ADYACENTE O SUPERPUESTA A LA PRIMERA CAPA, EN LA QUE EL CLORHIDRATO DE ALFUZASINA ES VEHICULADO, ESTANDO ESTA CAPA FORMULADA CON POLIMEROS HIDROFILOS Y CON OTRAS SUSTANCIAS AUXILIARES, PARA DAR A LA PREPARACION PROPIEDADES DE COMPRESIBILIDAD ADECUADA Y PARA PERMITIR LA LIBERACION DE CLORHIDRATO DE ALFUZOSINA EN UN INTERVALO DE TIEMPO PREDETERMINADO, C) Y OPCIONALMENTE UNA TERCERA CAPA (3) OBTENIDA POR COMPRESION Y APLICADA EN LA CAPA (2), GENERALMENTE CONSTITUIDA EN PARTICULAR POR POLIMEROS HIDROFILOS QUE SE GELIFICAN Y/O SE INFLAN Y A CONTINUACION PUEDEN OPCIONALMENTE DESGASTAR Y QUE TIENEN UNA FUNCION DE BARRERA QUE MODULA LA LIBERACION DEL CHORHIDRATO DE ALFUZOSINA DE LA CAPA (2), SIENDO LA CAPA (3) EN UN PRIMER LUGAR MUY POCO PERMEABLE AL PASO DE LA SUSTANCIA ACTIVA. COMPOSICION FARMACEUTICA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9610551A FR2752737B1 (fr) | 1996-08-29 | 1996-08-29 | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
FR9704386 | 1997-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2159400T3 true ES2159400T3 (es) | 2001-10-01 |
Family
ID=26232935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97937651T Expired - Lifetime ES2159400T3 (es) | 1996-08-29 | 1997-08-22 | Comprimido con liberacion controlada de clorhidrato de alfuzosina |
Country Status (37)
Country | Link |
---|---|
US (1) | US6149940A (es) |
EP (1) | EP0938318B1 (es) |
JP (1) | JP3797388B2 (es) |
KR (1) | KR100364328B1 (es) |
CN (2) | CN1155382C (es) |
AP (1) | AP1107A (es) |
AR (1) | AR009312A1 (es) |
AT (1) | ATE200864T1 (es) |
AU (1) | AU724490B2 (es) |
BG (1) | BG63768B1 (es) |
BR (1) | BR9713237B1 (es) |
CA (1) | CA2264250C (es) |
CO (1) | CO4920217A1 (es) |
CY (1) | CY2284B1 (es) |
CZ (1) | CZ295066B6 (es) |
DE (1) | DE69704712T2 (es) |
DK (1) | DK0938318T3 (es) |
EE (1) | EE03855B1 (es) |
ES (1) | ES2159400T3 (es) |
GR (1) | GR3036291T3 (es) |
HK (1) | HK1020875A1 (es) |
HU (1) | HU228007B1 (es) |
IL (1) | IL128146A (es) |
IS (1) | IS2091B (es) |
MX (1) | MXPA99001958A (es) |
NO (1) | NO326206B1 (es) |
NZ (1) | NZ334018A (es) |
OA (1) | OA10983A (es) |
PL (1) | PL191546B1 (es) |
PT (1) | PT938318E (es) |
RU (1) | RU2183459C2 (es) |
SI (1) | SI0938318T1 (es) |
SK (1) | SK284388B6 (es) |
TR (1) | TR199900289T2 (es) |
TW (1) | TW522023B (es) |
UA (1) | UA69374C2 (es) |
WO (1) | WO1998008515A1 (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6720471B1 (en) | 1998-04-28 | 2004-04-13 | The Procter & Gamble Company | Absorbent articles having reduced rewet with distribution materials positioned underneath storage material |
US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
FR2784583B1 (fr) * | 1998-10-16 | 2002-01-25 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
ATE340563T1 (de) * | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
FR2820318B1 (fr) * | 2001-02-08 | 2005-12-23 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu |
FR2820319B3 (fr) * | 2001-02-08 | 2003-12-05 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu |
US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
US7163696B2 (en) * | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
US6852238B2 (en) * | 2002-08-29 | 2005-02-08 | Steller Technology Company | Layered tablet water treatment compositions and method of use |
US7309444B2 (en) * | 2002-08-29 | 2007-12-18 | Stellar Technology Company | Layered tablet water treatment compositions and method of use |
DK1551372T3 (en) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
MXPA05004338A (es) * | 2002-10-22 | 2005-06-22 | Ranbaxy Lab Ltd | Composiciones de liberacion sostenida que contienen alfuzosin. |
AU2005266459A1 (en) * | 2004-07-29 | 2006-02-02 | Sanofi-Aventis | Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility |
FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
US20060062846A1 (en) * | 2004-09-17 | 2006-03-23 | Cimex Pharma Ag | Alfuzosin tablets and synthesis |
US20060062845A1 (en) * | 2004-09-17 | 2006-03-23 | Cimex Pharma Ag | Alfuzosin tablets and synthesis |
ITMI20050391A1 (it) * | 2005-03-11 | 2006-09-12 | Ph & T S P A | Formulazioni a rilascio controllato di alfuzosin |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
EP2392258B1 (en) | 2005-04-28 | 2014-10-08 | Proteus Digital Health, Inc. | Pharma-informatics system |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
CN101184780B (zh) | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
US20070185236A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive compositions |
US20070185235A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive compositions |
US20070185232A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
US20090238776A1 (en) * | 2005-11-09 | 2009-09-24 | Arif Ali Baig | Oral Care Compositions and Methods |
US7834066B2 (en) * | 2005-11-09 | 2010-11-16 | The Procter & Gamble Company | Denture adhesive articles |
US20070185237A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
US20070185233A1 (en) * | 2005-11-09 | 2007-08-09 | Jayanth Rajaiah | Denture adhesive articles |
US20070129460A1 (en) * | 2005-11-09 | 2007-06-07 | Jayanth Rajaiah | Denture adhesive articles |
EP1976488A4 (en) * | 2006-01-12 | 2010-02-10 | Wockhardt Ltd | ALFUZOSIN PROLONGED RELEASE PREPARATIONS |
CN105468895A (zh) | 2006-05-02 | 2016-04-06 | 普罗透斯数字保健公司 | 患者定制的治疗方案 |
CN101677963B (zh) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | 药物组合物 |
US20080003286A1 (en) * | 2006-06-29 | 2008-01-03 | Sathya Narayana Vemula | Sustained delivery alfuzosin compositions |
JPWO2008041553A1 (ja) | 2006-09-26 | 2010-02-04 | アステラス製薬株式会社 | タクロリムス徐放性製剤 |
US20080095844A1 (en) * | 2006-10-23 | 2008-04-24 | Rajhans Sujay Kamalakar | Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof |
EP2083680B1 (en) | 2006-10-25 | 2016-08-10 | Proteus Digital Health, Inc. | Controlled activation ingestible identifier |
EP2069004A4 (en) | 2006-11-20 | 2014-07-09 | Proteus Digital Health Inc | PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING |
US20080138412A1 (en) * | 2006-12-06 | 2008-06-12 | Fu-Yung Lin | Sustained release alfuzosin hydrochl formulation and method for their production |
WO2008073388A2 (en) * | 2006-12-11 | 2008-06-19 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making and methods of use |
US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
JPWO2008084698A1 (ja) | 2006-12-28 | 2010-04-30 | アステラス製薬株式会社 | タクロリムス徐放性医薬組成物 |
MY165532A (en) | 2007-02-01 | 2018-04-02 | Proteus Digital Health Inc | Ingestible event marker systems |
CA2676280C (en) | 2007-02-14 | 2018-05-22 | Proteus Biomedical, Inc. | In-body power source having high surface area electrode |
WO2008102235A1 (en) * | 2007-02-20 | 2008-08-28 | Aurobindo Pharma Limited | Controlled release formulations of alfuzosin |
EP2124725A1 (en) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
DK2192946T3 (da) | 2007-09-25 | 2022-11-21 | Otsuka Pharma Co Ltd | Kropsintern anordning med virtuel dipol signalforstærkning |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
MY161533A (en) | 2008-03-05 | 2017-04-28 | Proteus Digital Health Inc | Multi-mode communication ingestible event markers and systems, and methods of using the same |
WO2009149029A2 (en) * | 2008-06-04 | 2009-12-10 | The Procter & Gamble Company | Denture adhesive compositions and methods |
SG195535A1 (en) | 2008-07-08 | 2013-12-30 | Proteus Digital Health Inc | Ingestible event marker data framework |
KR101214453B1 (ko) | 2008-08-13 | 2012-12-24 | 프로테우스 디지털 헬스, 인코포레이티드 | 복용 가능한 회로 |
US20100233259A1 (en) * | 2008-12-12 | 2010-09-16 | Pascal Grenier | Dosage form of ropinirole |
AU2010203625A1 (en) | 2009-01-06 | 2011-07-21 | Proteus Digital Health, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
TWI602561B (zh) | 2009-01-06 | 2017-10-21 | 波提亞斯數位康健公司 | 醫藥劑量傳送系統 |
US20100183717A1 (en) * | 2009-01-16 | 2010-07-22 | Kristin Arnold | Controlled-release formulations |
WO2010111403A2 (en) | 2009-03-25 | 2010-09-30 | Proteus Biomedical, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
CN102458236B (zh) | 2009-04-28 | 2016-01-27 | 普罗秋斯数字健康公司 | 高可靠性的可摄入事件标记器及其使用方法 |
WO2010132331A2 (en) | 2009-05-12 | 2010-11-18 | Proteus Biomedical, Inc. | Ingestible event markers comprising an ingestible component |
TWI517050B (zh) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | 供應鏈管理之系統 |
BR112012022646A2 (pt) | 2010-03-10 | 2016-08-23 | Procter & Gamble | composições adesivas para dentaduras |
PL2554168T3 (pl) | 2010-03-29 | 2018-05-30 | Astellas Pharma Inc. | Kompozycja farmaceutyczna do kontrolowanego uwalniania |
WO2011127252A2 (en) | 2010-04-07 | 2011-10-13 | Proteus Biomedical, Inc. | Miniature ingestible device |
EP2555756B1 (en) * | 2010-04-07 | 2018-08-22 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
TWI557672B (zh) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置 |
JP2014504902A (ja) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス, インコーポレイテッド | 医薬品を有する摂取可能なデバイス |
CN102475690B (zh) * | 2010-11-30 | 2016-06-01 | 安国药品株式会社 | 内含盐酸阿夫唑嗪的缓释片剂 |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
BR112014001397A2 (pt) | 2011-07-21 | 2017-02-21 | Proteus Biomedical Inc | dispositivo, sistema e método de comunicação móvel |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
WO2014018454A1 (en) | 2012-07-23 | 2014-01-30 | Proteus Digital Health, Inc. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
JP5869736B2 (ja) | 2012-10-18 | 2016-02-24 | プロテウス デジタル ヘルス, インコーポレイテッド | 通信デバイス用の電源において電力消失およびブロードキャスト電力を適応的に最適化するための装置、システム、および方法 |
TWI659994B (zh) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | 高度可膨脹之聚合型薄膜及包含彼之組成物 |
JP5941240B2 (ja) | 2013-03-15 | 2016-06-29 | プロテウス デジタル ヘルス, インコーポレイテッド | 金属検出器装置、システム、および方法 |
JP6511439B2 (ja) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | データ収集および転帰の査定のためのシステム、装置、および方法 |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
WO2017078557A1 (ru) * | 2015-11-05 | 2017-05-11 | Анатолий Викторович ЗАЗУЛЯ | Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога |
KR20210018961A (ko) | 2016-07-22 | 2021-02-18 | 프로테우스 디지털 헬스, 인코포레이티드 | 섭취 가능한 이벤트 마커의 전자기 감지 및 검출 |
IL265827B2 (en) | 2016-10-26 | 2023-03-01 | Proteus Digital Health Inc | Methods for producing capsules with ingestible event markers |
CN114209668B (zh) * | 2022-01-13 | 2023-01-31 | 山东新时代药业有限公司 | 一种盐酸阿夫唑嗪缓释制剂及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2582513B1 (fr) * | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
IT1237904B (it) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
GB9311191D0 (en) * | 1993-05-29 | 1993-07-14 | Danbiosyst Uk | Controlled release drug formulation |
FR2717388B1 (fr) * | 1994-03-21 | 1996-11-22 | Synthelabo | Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine. |
-
1997
- 1997-08-22 SI SI9730158T patent/SI0938318T1/xx unknown
- 1997-08-22 PL PL331862A patent/PL191546B1/pl unknown
- 1997-08-22 US US09/147,581 patent/US6149940A/en not_active Expired - Lifetime
- 1997-08-22 CA CA002264250A patent/CA2264250C/en not_active Expired - Lifetime
- 1997-08-22 AU AU40201/97A patent/AU724490B2/en not_active Expired
- 1997-08-22 AT AT97937651T patent/ATE200864T1/de active
- 1997-08-22 SK SK270-99A patent/SK284388B6/sk not_active IP Right Cessation
- 1997-08-22 IL IL12814697A patent/IL128146A/xx not_active IP Right Cessation
- 1997-08-22 BR BRPI9713237-3A patent/BR9713237B1/pt not_active IP Right Cessation
- 1997-08-22 DE DE69704712T patent/DE69704712T2/de not_active Expired - Lifetime
- 1997-08-22 CZ CZ1999655A patent/CZ295066B6/cs not_active IP Right Cessation
- 1997-08-22 DK DK97937651T patent/DK0938318T3/da active
- 1997-08-22 EE EEP199900090A patent/EE03855B1/xx unknown
- 1997-08-22 ES ES97937651T patent/ES2159400T3/es not_active Expired - Lifetime
- 1997-08-22 PT PT97937651T patent/PT938318E/pt unknown
- 1997-08-22 UA UA99020755A patent/UA69374C2/uk unknown
- 1997-08-22 HU HU9903428A patent/HU228007B1/hu unknown
- 1997-08-22 RU RU99105730/14A patent/RU2183459C2/ru active
- 1997-08-22 JP JP51133198A patent/JP3797388B2/ja not_active Expired - Lifetime
- 1997-08-22 TR TR1999/00289T patent/TR199900289T2/xx unknown
- 1997-08-22 MX MXPA99001958A patent/MXPA99001958A/es active IP Right Grant
- 1997-08-22 AP APAP/P/1999/001470A patent/AP1107A/en active
- 1997-08-22 EP EP97937651A patent/EP0938318B1/fr not_active Expired - Lifetime
- 1997-08-22 NZ NZ334018A patent/NZ334018A/xx not_active IP Right Cessation
- 1997-08-22 WO PCT/FR1997/001515 patent/WO1998008515A1/fr active IP Right Grant
- 1997-08-22 CN CNB971975582A patent/CN1155382C/zh not_active Expired - Lifetime
- 1997-08-22 KR KR1019997001666A patent/KR100364328B1/ko not_active IP Right Cessation
- 1997-08-22 CN CNB2004100422955A patent/CN100335057C/zh not_active Expired - Lifetime
- 1997-08-25 AR ARP970103839A patent/AR009312A1/es active IP Right Grant
- 1997-08-26 TW TW086112274A patent/TW522023B/zh not_active IP Right Cessation
- 1997-08-28 CO CO97049830A patent/CO4920217A1/es unknown
-
1999
- 1999-01-29 IS IS4964A patent/IS2091B/is unknown
- 1999-02-01 BG BG103138A patent/BG63768B1/bg unknown
- 1999-02-26 OA OA9900042A patent/OA10983A/fr unknown
- 1999-02-26 NO NO19990944A patent/NO326206B1/no not_active IP Right Cessation
- 1999-12-20 HK HK99105968A patent/HK1020875A1/xx not_active IP Right Cessation
-
2001
- 2001-07-26 GR GR20010401141T patent/GR3036291T3/el unknown
-
2002
- 2002-05-15 CY CY0200038A patent/CY2284B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2159400T3 (es) | Comprimido con liberacion controlada de clorhidrato de alfuzosina | |
ES2126536B1 (es) | "preparado farmaceutico para administracion intranasal y procedimientopara su produccion". | |
CO4340618A1 (es) | Composicion farmaceutica para liberacion controlada | |
SE0003449L (sv) | Cancerhämmande kompositioner | |
ES2112387T3 (es) | Composiciones farmaceuticas que contienen simeticona para el tratamiento de problemas gastrointestinales. | |
ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
EA200300045A1 (ru) | Композиция и лекарственная форма для задерживаемого желудочного выделения алендроната и/или других бис-фосфонатов | |
CR6326A (es) | Formulaciones farmaceuticas de liberacion controlada | |
AR030557A1 (es) | Una tableta en multicapa de liberacion controlada y metodo de tratamiento | |
ATE235895T1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
WO2002060385A3 (en) | Pharmaceutical formulation | |
ES2031491T3 (es) | Tableta para uso farmaceutico capaz de liberar sustancias activas en momentos sucesivos. | |
DK136186A (da) | Laegemiddelbaerer | |
ATE158176T1 (de) | Ein guanidinothiazol und antazida enthaltende arzneimittel | |
CO5611118A2 (es) | Formulaciones de azitromicina granuladas por via seca | |
CO5011053A1 (es) | Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento | |
BR9807992A (pt) | Comprimidos para engolir os quais compreendem paracetamol | |
DE69825164D1 (de) | Arzneizubereitungen enthaltend vitamin d und kalzium,ihre herstellung und therapeutische verwendung | |
GT200000111A (es) | Procedimiento para la obtencion de preparados farmaceuticos solidos de disgregacion rapida. | |
DE69716469D1 (de) | Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol | |
ATE303137T1 (de) | Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit | |
DE60042831D1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
DE60025503D1 (de) | Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten | |
DE60206871D1 (de) | Pharmazeutische Formulierung enhaltend Midazolam zur buccalen Verabreichung | |
HRP20000781B1 (en) | Effervescent preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 938318 Country of ref document: ES |